Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

11.46
-2.0100-14.92%
Post-market: 11.44-0.0200-0.17%19:48 EDT
Volume:786.67K
Turnover:9.15M
Market Cap:169.70M
PE:-0.47
High:13.63
Open:13.62
Low:9.67
Close:13.47
Loading ...

Lyell Immunopharma Inc - to Close West Hills Manufacturing Facility - SEC Filing

THOMSON REUTERS
·
02 Apr

Lyell Immunopharma Inc: Reiterates Its Financial Guidance

THOMSON REUTERS
·
02 Apr

Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report

TIPRANKS
·
23 Mar

Favourable Signals For Lyell Immunopharma: Numerous Insiders Acquired Stock

Simply Wall St.
·
20 Mar

Lyell Immunopharma Price Target Maintained With a $1.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

Lyell Immunopharma’s Global Expansion Strategy: Navigating Risks and Challenges

TIPRANKS
·
13 Mar

Lyell Immunopharma Q4 Sales $11.00K Down From $13.00K YoY

Benzinga
·
12 Mar

BRIEF-Lyell Immunopharma Q4 Net Income USD -191.935 Million

Reuters
·
12 Mar

Lyell Immunopharma Q4 Revenue USD 11 Thousand

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Q4 Operating Expenses USD 201.158 Million

THOMSON REUTERS
·
12 Mar

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners

Simply Wall St.
·
17 Feb

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake

Simply Wall St.
·
31 Jan

Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why

Zacks
·
23 Jan

Lyell Immunopharma price target lowered to 60c from $1 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)

Zacks
·
30 Dec 2024

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
24 Dec 2024

Lyell Immunopharma presents positive data from Phase 1-2 IMPT-314 study

TIPRANKS
·
10 Dec 2024

BRIEF-Lyell Immunopharma Says Impt-314 Receives Fast Track Designation From FDA

Reuters
·
10 Dec 2024